相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis
Qi Tian et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2022)
Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
Milton Packer
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study
Sharen Lee et al.
ACTA DIABETOLOGICA (2021)
Metabolic and Signaling Roles of Ketone Bodies in Health and Disease
Patrycja Puchalska et al.
Annual Review of Nutrition (2021)
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages
Akira Mima
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials
Wei Qu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis
Mattia Albiero et al.
DIABETES (2021)
SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
Giovanna Leoncini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study
Kirsten Thiele et al.
DIABETES OBESITY & METABOLISM (2021)
The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Jiang Liu et al.
JOURNAL OF MEMBRANE BIOLOGY (2021)
Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus
Habib Yaribeygi et al.
BIOMED RESEARCH INTERNATIONAL (2021)
Beneficial effects of empagliflozin on hematocrit levels in a patient with severe anemia
Jan Budzianowski et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective
Danubia Silva dos Santos et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer et al.
CIRCULATION (2020)
Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy
Yafeng Li et al.
EYE (2020)
Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
Habib Yaribeygi et al.
LIFE SCIENCES (2020)
Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Habib Yaribeygi et al.
LIFE SCIENCES (2020)
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Benedetta Maria Bonora et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice
Ting Cai et al.
CELL DEATH & DISEASE (2020)
Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile
Emir Muzurovic et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
When Good Guys Turn Bad: Bone Marrow's and Hematopoietic Stem Cells' Role in the Pathobiology of Diabetic Complications
Maria Cristina Vinci et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha
Angelamellisy Revelian Ndibalema et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention
Jinli Liu et al.
BMC PUBLIC HEALTH (2020)
Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes
Milton Packer
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders
Milton Packer
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules
Jinpeng Li et al.
JCI INSIGHT (2020)
Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases
Rosi Bissinger et al.
FEBS JOURNAL (2019)
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
Motoaki Sano et al.
CIRCULATION (2019)
Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
Takashi Maruyama et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
Ryoichi Bessho et al.
SCIENTIFIC REPORTS (2019)
Sodium-glucose cotransporter inhibitors and oxidative stress: An update
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes
Eiji Kutoh et al.
DRUG RESEARCH (2019)
Oxidative stress induces renal failure: A review of possible molecular pathways
Habib Yaribeygi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Physiology and pathophysiology of renal erythropoietin-producing cells
Hong-Mou Shih et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2018)
Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
Shinji Tanaka et al.
KIDNEY INTERNATIONAL (2018)
Human Mesenchymal Stem Cells Expressing Erythropoietin Enhance Survivability of Retinal Neurons Against Oxidative Stress: An In Vitro Study
Suet Lee Shirley Ding et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2018)
Ketone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake
Katrine M. Lauritsen et al.
DIABETES CARE (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Daiji Kawanami et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation
Keisuke Oshima et al.
LABORATORY INVESTIGATION (2017)
Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes
Li Tang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus
Atsunori Kashiwagi et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD
Nupur Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Patrycja Puchalska et al.
CELL METABOLISM (2017)
Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling
Tomokazu Souma et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease
Yalcin Solak et al.
BLOOD PURIFICATION (2016)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
Erythropoietin-regulated oxidative stress negatively affects enucleation during terminal erythropoiesis
Baobing Zhao et al.
EXPERIMENTAL HEMATOLOGY (2016)
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
Matthias Kern et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Yoon-Kyung Chang et al.
PLOS ONE (2016)
SGLT2 inhibitors in the management of type 2 diabetes
R. P. Monica Reddy et al.
ENDOCRINE (2016)
Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice
Takashi Hatanaka et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
Acute SGLT inhibition normalizes O-2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats
Julie O'Neill et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2014)
Hypoxia-inducible Factor-1α (HIF-1α) Protein Diminishes Sodium Glucose Transport 1 (SGLT1) and SGLT2 Protein Expression in Renal Epithelial Tubular Cells (LLC-PK1) under Hypoxia
Juan R. Zapata-Morales et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients With Type 2 Diabetes
Jaime A. Davidson et al.
POSTGRADUATE MEDICINE (2014)
Ketone bodies as signaling metabolites
John C. Newman et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2014)
Regulation of erythropoiesis by hypoxia-inducible factors
Volker H. Haase
BLOOD REVIEWS (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy?
Usha Panchapakesan et al.
PLOS ONE (2013)
Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
Horacio Osorio et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2012)
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Christine Clar et al.
BMJ OPEN (2012)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Erythropoietin Couples Hematopoiesis with Bone Formation
Yusuke Shiozawa et al.
PLOS ONE (2010)
Hypoxic regulation of erythropoiesis and iron metabolism
Volker H. Haase
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
Hematopoiesis: An evolving paradigm for stem cell biology
Stuart H. Orkin et al.
CELL (2008)
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Songping Han et al.
DIABETES (2008)
Enhanced programmed cell death of iron-deficient erythrocytes
Daniela S. Kempe et al.
FASEB JOURNAL (2006)
分享论文
